share_log

Enanta Pharmaceuticals Presenting Preclinical Data for Its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) Programs at the 12th International RSV Symposium

Benzinga Real-time News ·  Sep 29, 2022 07:12

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data related to its RSV program, as well as new virology methods used for its RSV and hMPV programs, will be presented during the 12th International RSV Symposium at ICC Belfast in Northern Ireland, United Kingdom. An oral presentation and poster highlight the preclinical characteristics and the in vivo efficacy of EDP-323, a novel non-nucleoside RSV L-inhibitor. Additional posters characterize a 3D culture model for studying RSV, as well as outline methods for improved...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment